Evidence map›Paper›PMID 41669309›Full record

ArticleAdvanced biomedical research2025

Promoter Methylation of

Amir Mohamad Mohamadizad Moghadam, Yousef Mohammadi, Shahrouz Khoshbakht, Ruhollah Mirjani, Ali Zarei, Mohsen Ghasemzadeh Soroush, Seyyed Mohamad Hoseini, Meysam Mosallaei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amir Mohamad Mohamadizad MoghadamStudent Research Committee, Aja University of Medical Sciences, Tehran, Iran.
Yousef MohammadiStudent Research Committee, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Shahrouz KhoshbakhtGenome Medical Genetics Lab, Arak, Iran.
Ruhollah MirjaniDepartment of Genetics and Advanced Technologies, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
Ali ZareiDepartment of Genetics and Advanced Technologies, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
Mohsen Ghasemzadeh SoroushDepartment of Rheumatology, Aja University of Medical Sciences, Imam Reza Hospital, Tehran, Iran.
Seyyed Mohamad HoseiniDepartment of Pediatric, Semnan University of Medical Sciences, Semnan, Iran.
Meysam MosallaeiPersonalized Medicine and Genometabolomics Research Center, Hope Generation Foundation, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint damage. Conventional diagnostic markers for RA have limitations, prompting the exploration of DNA methylation analysis as a potential biomarker. This study focuses on evaluating the methylation levels of two genes, Materials and Methods: We assessed the methylation levels of the Results: Conclusion: The study suggests that

Indexed as

BiomarkermethylationMMP9 generheumatoid arthritisRUNX3 gene

Identifiers

PMID41669309
PMCPMC12885186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.